136 related articles for article (PubMed ID: 12928361)
1. Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain.
Calzascia T; Di Berardino-Besson W; Wilmotte R; Masson F; de Tribolet N; Dietrich PY; Walker PR
J Immunol; 2003 Sep; 171(5):2187-91. PubMed ID: 12928361
[TBL] [Abstract][Full Text] [Related]
2. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells.
Walker PR; Calzascia T; Schnuriger V; Scamuffa N; Saas P; de Tribolet N; Dietrich PY
J Immunol; 2000 Sep; 165(6):3128-35. PubMed ID: 10975826
[TBL] [Abstract][Full Text] [Related]
3. Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus.
Basler M; Youhnovski N; Van Den Broek M; Przybylski M; Groettrup M
J Immunol; 2004 Sep; 173(6):3925-34. PubMed ID: 15356141
[TBL] [Abstract][Full Text] [Related]
4. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes.
Blohm U; Roth E; Brommer K; Dumrese T; Rosenthal FM; Pircher H
J Immunol; 2002 Nov; 169(10):5522-30. PubMed ID: 12421928
[TBL] [Abstract][Full Text] [Related]
5. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles.
Storni T; Lechner F; Erdmann I; Bächi T; Jegerlehner A; Dumrese T; Kündig TM; Ruedl C; Bachmann MF
J Immunol; 2002 Mar; 168(6):2880-6. PubMed ID: 11884458
[TBL] [Abstract][Full Text] [Related]
6. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL.
Nelson DJ; Mukherjee S; Bundell C; Fisher S; van Hagen D; Robinson B
J Immunol; 2001 May; 166(9):5557-66. PubMed ID: 11313395
[TBL] [Abstract][Full Text] [Related]
7. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation.
Stumbles PA; Himbeck R; Frelinger JA; Collins EJ; Lake RA; Robinson BW
J Immunol; 2004 Nov; 173(10):5923-8. PubMed ID: 15528325
[TBL] [Abstract][Full Text] [Related]
8. CTL induction by cross-priming is restricted to immunodominant epitopes.
Pavelic V; Matter MS; Mumprecht S; Breyer I; Ochsenbein AF
Eur J Immunol; 2009 Mar; 39(3):704-16. PubMed ID: 19189311
[TBL] [Abstract][Full Text] [Related]
9. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity.
Gordon LB; Nolan SC; Cserr HF; Knopf PM; Harling-Berg CJ
J Immunol; 1997 Sep; 159(5):2399-408. PubMed ID: 9278331
[TBL] [Abstract][Full Text] [Related]
10. The signal sequence of lymphocytic choriomeningitis virus contains an immunodominant cytotoxic T cell epitope that is restricted by both H-2D(b) and H-2K(b) molecules.
Hudrisier D; Oldstone MB; Gairin JE
Virology; 1997 Jul; 234(1):62-73. PubMed ID: 9234947
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
[TBL] [Abstract][Full Text] [Related]
12. The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes.
Schirmbeck R; Stober D; El-Kholy S; Riedl P; Reimann J
J Immunol; 2002 Jun; 168(12):6253-62. PubMed ID: 12055239
[TBL] [Abstract][Full Text] [Related]
13. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
[TBL] [Abstract][Full Text] [Related]
14. The outcome of cross-priming during virus infection is not directly linked to the ability of the antigen to be cross-presented.
Alatery A; Tarrab E; Lamarre A; Basta S
Eur J Immunol; 2010 Aug; 40(8):2190-9. PubMed ID: 20518030
[TBL] [Abstract][Full Text] [Related]
15. Requirements for bone marrow-derived antigen-presenting cells in priming cytotoxic T cell responses to intracellular pathogens.
Lenz LL; Butz EA; Bevan MJ
J Exp Med; 2000 Oct; 192(8):1135-42. PubMed ID: 11034603
[TBL] [Abstract][Full Text] [Related]
16. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors.
Schirmbeck R; Böhm W; Reimann J
J Immunol; 1996 Oct; 157(8):3550-8. PubMed ID: 8871655
[TBL] [Abstract][Full Text] [Related]
17. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus. I. Generation and recognition of virus strains and H-2b mutants.
Byrne JA; Ahmed R; Oldstone MB
J Immunol; 1984 Jul; 133(1):433-9. PubMed ID: 6202788
[TBL] [Abstract][Full Text] [Related]
18. Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression.
Probst HC; Tschannen K; Gallimore A; Martinic M; Basler M; Dumrese T; Jones E; van den Broek MF
J Immunol; 2003 Nov; 171(10):5415-22. PubMed ID: 14607945
[TBL] [Abstract][Full Text] [Related]
19. Mapping of HLA epitopes recognized by H-2-restricted cytotoxic T lymphocytes specific for HLA using recombinant genes and synthetic peptides.
Pala P; Corradin G; Strachan T; Sodoyer R; Jordan BR; Cerottini JC; Maryanski JL
J Immunol; 1988 Feb; 140(3):871-7. PubMed ID: 2448379
[TBL] [Abstract][Full Text] [Related]
20. In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes.
Nelson D; Bundell C; Robinson B
J Immunol; 2000 Dec; 165(11):6123-32. PubMed ID: 11086045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
